<?xml version="1.0" encoding="UTF-8"?>
<ref id="B66">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Grinsztejn</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Nguyen</surname>
    <given-names>B.-Y.</given-names>
   </name>
   <name>
    <surname>Katlama</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Gatell</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Vittecoq</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2007</year>). 
  <article-title>Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial</article-title>. 
  <source>Lancet</source>
  <volume>369</volume> (
  <issue>9569</issue>), 
  <fpage>1261</fpage>â€“
  <lpage>1269</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60597-2</pub-id>
  <pub-id pub-id-type="pmid">17434401</pub-id>
 </mixed-citation>
</ref>
